Diet and Fecal Incontinence in Senior Women
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03510052 |
|
Recruitment Status :
Completed
First Posted : April 27, 2018
Last Update Posted : January 25, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Accidental Bowel Leakage Fecal Incontinence Incontinence Bowel Incontinence | Behavioral: Diet Modification Pilot Program (DPM) | Not Applicable |
Study Procedure: Visit Schedule
Visit 1(Baseline visit): Following consent, the study coordinator will obtain participant's demographic data including age, race/ethnicity, body mass index. Data on medical comorbidities, surgical history and medications known to be associated with FI will be collected. The participant's severity of FI will be measured using the St. Mark's Vaizey scale (Vaizey). The impact of FI on quality of life will be measured using the Fecal Incontinence Quality of Life scale (FIQL). The presence, type, and severity of other pelvic floor symptoms known to be associated with FI will be assessed using the Pelvic floor Distress Inventory- Short Form. Participants will be given a Food and Bowel Symptom diary and a stool collection kit at the conclusion of the visit.
Visit 2(Intervention visit): Stool sample will be collected by the study coordinator. Investigators will administer the DMP. Participants will be given the booklet outlining the DMP and investigators will review the participant's Food and Symptom diary and provide targeted recommendations. The participant will be given a second Food and Symptom diary and stool collection kit to return 6 weeks after the intervention start date.
Calls: Trained Nutritionists will call the participant between weeks 2 and 4 for three unannounced 24h diet recall. The 24-hour dietary recalls will be collected using Nutrition Data System for Research, a computer-based software application that facilitates the collection of recalls in a standardized fashion.
Visit 3 (Follow up visit): Post intervention stool samples and Food and Symptom diary will be collected. Questionnaires including the Vaizey, FIQL, Pelvic Floow Disability Index (PFDI), and Patient Global Index of Improvement (PGI-I) will be administered by the study coordinator. Participants will receive compensation for participating in the study.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 55 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Diet Modification Program for Senior Women With Fecal Incontinence |
| Actual Study Start Date : | February 1, 2018 |
| Actual Primary Completion Date : | December 1, 2020 |
| Actual Study Completion Date : | December 1, 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Diet Modification Pilot Program
Investigator will administer DMP which will include a review of the booklets and any targeted recommendations based on the participant's food and symptom diary. The participant will follow the DMP for 6 weeks and report for a follow-up visit.
|
Behavioral: Diet Modification Pilot Program (DPM)
Investigator will administer DMP which will include a review of the booklets and any targeted recommendations based on the participant's food and symptom diary. The participant will follow the DMP for 6 weeks and report for a follow-up visit. |
- Change in FI Symptoms (Vaizey) [ Time Frame: 6 weeks ]Changes in the participant's symptom severity will be assessed from baseline to study conclusion.
- Changes in stool metabolites [ Time Frame: 6 weeks ]Change from baseline in levels of stool deoxycholic acid(DCA, µmol/g feces)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 65 Years and older (Older Adult) |
| Sexes Eligible for Study: | Female |
| Gender Based Eligibility: | Yes |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age ≥ 65 years,
- FI defined as any uncontrolled loss of liquid or solid fecal material that occurs at least monthly over the last 3 months that is bothersome enough to desire treatment,
- adequate mobility for independent toileting,
- ability for independent completion of food symptom diary,
- has some control of her diet and is able to make adjustments
- able to read and communicate in English,
- willing to give informed consent
Exclusion Criteria:
- Currently receiving another treatment for FI
- significant cognitive impairment at baseline
- residence in a care facility that provides meals (participants who are not able to adjust their diet will be excluded because the intervention focuses on the participant, not their care facility)
- current bloody diarrhea,
- current or past diagnosis of colorectal
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03510052
| United States, Pennsylvania | |
| Hospital of the University of Pennsylvania | |
| Philadelphia, Pennsylvania, United States, 19104 | |
| Principal Investigator: | Uduak U Andy, MD | University of Pennsylvania |
| Responsible Party: | University of Pennsylvania |
| ClinicalTrials.gov Identifier: | NCT03510052 |
| Other Study ID Numbers: |
825518 |
| First Posted: | April 27, 2018 Key Record Dates |
| Last Update Posted: | January 25, 2021 |
| Last Verified: | January 2021 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
diet Fecal Incontinence FI ABL |
|
Fecal Incontinence Rectal Diseases Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases |

